Dan Levitt

840 total citations
16 papers, 466 citations indexed

About

Dan Levitt is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Dan Levitt has authored 16 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Dan Levitt's work include Allergic Rhinitis and Sensitization (3 papers), Angiogenesis and VEGF in Cancer (3 papers) and Immunotherapy and Immune Responses (2 papers). Dan Levitt is often cited by papers focused on Allergic Rhinitis and Sensitization (3 papers), Angiogenesis and VEGF in Cancer (3 papers) and Immunotherapy and Immune Responses (2 papers). Dan Levitt collaborates with scholars based in United States, Netherlands and Austria. Dan Levitt's co-authors include C. K. Osborne, Gary M. Clark, Feng Wu, Simon Dobson, Joanne M. Langley, Gary Van Nest, Shelly McNeil, J. Zeffren, Daniel Gennevois and Joseph Eiden and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Dan Levitt

16 papers receiving 440 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dan Levitt United States 10 189 145 119 118 64 16 466
Chang‐Ho Jeon South Korea 13 175 0.9× 169 1.2× 189 1.6× 70 0.6× 51 0.8× 56 592
S Sugai Japan 10 237 1.3× 123 0.8× 142 1.2× 77 0.7× 117 1.8× 31 592
M J Whitters United States 8 393 2.1× 148 1.0× 76 0.6× 121 1.0× 31 0.5× 12 618
Marie L. Hoover United States 13 288 1.5× 115 0.8× 92 0.8× 14 0.1× 65 1.0× 23 1.1k
Anne Månsson Kvarnhammar Sweden 10 283 1.5× 83 0.6× 157 1.3× 148 1.3× 52 0.8× 16 532
Monique Stevens Belgium 12 287 1.5× 119 0.8× 159 1.3× 57 0.5× 31 0.5× 15 536
F.W. Busch Germany 11 171 0.9× 124 0.9× 98 0.8× 22 0.2× 136 2.1× 26 499
M. Perricaudet France 5 154 0.8× 136 0.9× 100 0.8× 20 0.2× 66 1.0× 9 373
P Groshek United States 8 260 1.4× 116 0.8× 159 1.3× 26 0.2× 36 0.6× 10 559
Donna Hempel United States 10 163 0.9× 153 1.1× 126 1.1× 23 0.2× 111 1.7× 14 471

Countries citing papers authored by Dan Levitt

Since Specialization
Citations

This map shows the geographic impact of Dan Levitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Levitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Levitt more than expected).

Fields of papers citing papers by Dan Levitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Levitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Levitt. The network helps show where Dan Levitt may publish in the future.

Co-authorship network of co-authors of Dan Levitt

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Levitt. A scholar is included among the top collaborators of Dan Levitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Levitt. Dan Levitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Busse, W., et al.. (2006). Phase 2/3 Study of the Novel Vaccine Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate AIC in Ragweed-Allergic Adults. Journal of Allergy and Clinical Immunology. 117(2). S88–S89. 10 indexed citations
2.
Levitt, Dan, et al.. (2006). Novel Amb a 1 CpG Oligodeoxyribonucleotide Conjugate Ragweed Vaccine Administered to Children. Journal of Allergy and Clinical Immunology. 117(2). S159–S159. 5 indexed citations
3.
4.
Jayson, Gordon C., C Mulatero, Malcolm Ranson, et al.. (2005). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. European Journal of Cancer. 41(4). 555–563. 36 indexed citations
5.
6.
Jayson, Gordon C., Jamal Zweit, C Mulatero, et al.. (2001). PET and PK analysis of the humanized monoclonal anti-VEGF antibody HuMV833. An EORTC-biological treatment development group phase I study. European Journal of Cancer. 37. S101–S101. 1 indexed citations
7.
Jayson, Gordon C., C Mulatero, Malcolm Ranson, et al.. (2001). Anti-VEGF Antibody HuMV833: an EORTC Biological Treatment Development Group Phase I Toxicity, Pharmacokinetic and Pharmacodynamic Study.. Research Explorer (The University of Manchester). 17 indexed citations
8.
Hsu, Di‐Hwei, Jia Shi, Margit Homola, et al.. (1999). A HUMANIZED ANTI-CD3 ANTIBODY, HuM291, WITH LOW MITOGENIC ACTIVITY, MEDIATES COMPLETE AND REVERSIBLE T-CELL DEPLETION IN CHIMPANZEES. Transplantation. 68(4). 545–554. 35 indexed citations
9.
Clark, Gary M., et al.. (1997). Telomerase Activity and Survival of Patients With Node-Positive Breast Cancer. JNCI Journal of the National Cancer Institute. 89(24). 1874–1881. 128 indexed citations
10.
Whitehead, Robert P., Marc L. Citron, Nancy P. Moldawer, et al.. (1993). A Phase II Trial of Concomitant Human Interleukin-2 and Interferon-??-2a in Patients with Disseminated Malignant Melanoma. Journal of Immunotherapy. 13(2). 117–121. 19 indexed citations
11.
Bernstein, Zale P., Louis Vaickus, Neil Friedman, et al.. (1991). Interleukin-2 Lymphokine-Activated Killer Cell Therapy of Non-Hodgkinʼs Lymphoma and Hodgkinʼs Disease. Journal of Immunotherapy. 10(2). 141–146. 23 indexed citations
12.
Lipton, Allan, H Harvey, Kate Hopper, et al.. (1990). Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy.. Journal of Clinical Oncology. 8(10). 1657–1663. 57 indexed citations
13.
Brunda, Michael J., et al.. (1990). Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.. PubMed. 348. 61–9. 2 indexed citations
14.
Levitt, Dan, et al.. (1987). Development and regulation of chlamydia-responsive murine B lymphocytes.. The Journal of Immunology. 138(10). 3468–3474. 4 indexed citations
15.
Levitt, Dan, et al.. (1986). Both species of chlamydia and two biovars of Chlamydia trachomatis stimulate mouse B lymphocytes.. The Journal of Immunology. 136(11). 4249–4254. 13 indexed citations
16.
Levitt, Roy C., et al.. (1979). A single-gene difference associated with theophylline toxicity in mice. 27(2). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chang‐Ho Jeon Breakdown of academic impact, for papers by S Sugai Breakdown of academic impact, for papers by M J Whitters Breakdown of academic impact, for papers by Marie L. Hoover Breakdown of academic impact, for papers by Anne Månsson Kvarnhammar Breakdown of academic impact, for papers by Monique Stevens Breakdown of academic impact, for papers by F.W. Busch Breakdown of academic impact, for papers by M. Perricaudet Breakdown of academic impact, for papers by P Groshek Breakdown of academic impact, for papers by Donna Hempel
Rankless by CCL
2026